Arthritis & rheumatology (Hoboken, N.J.)
Weighing dose-related benefits and risks of hydroxychloroquine treatment in systemic lupus erythematosus patients.
Brian Meng-Hsun Li, Jia-Horung Hung, Po-Cheng Yang, Swu-Jane Lin, Edward Chia-Cheng Lai, Meng-Yu Weng
Published: 202510.1002/art.70022
Abstract
OBJECTIVE: To weigh higher-dose HCQ (>=400 mg/d) and lower-dose HCQ (<400 mg/d) for effectiveness and safety among patients with systemic lupus erythematosus (SLE). METHODS: This nationwide study retrieved data from Taiwan's National Health Insurance…
Preview only. Read the full abstract at the source